NRSN

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regainedNear-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027CAMBRIDGE, Mass., Oct. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that its hearing before the Nasdaq Hearings Panel (the "Panel") is scheduled for November 10, 2026, following its timely appeal of the Octobe

Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirementCAMBRIDGE, Mass., Oct. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that on October 1, 2026, it received a letter (the "Staff Determination") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has not regained complia

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

Management will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026 and will be available for one-on-one investor meetings during the conferenceCAMBRIDGE, Mass., Sept. 28, 2026  /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that Chief Financial Officer Or Eisenberg will participate in the 5th Annual ROTH Healthcare Opportunities Conference, taking place on Tuesday, September 29, 2026, at The Metropolitan Club in New York City.

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ -- Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today provided a business update with corporate highlights to date and financial results for the first half of 2026. NeuroSense is advancing PrimeC, its investigational combination therapy for amyotrophic lateral sclerosis (ALS), through regulatory pathways in the United States and Canada while pursuing a focused, capital-efficient late-stage development strategy."Our focus remains on advanc

Company presentation on Tuesday, September 15 at 4:30 p.m. ETManagement will be available for one-on-one investor meetings during the conferenceCAMBRIDGE, Mass., Sept. 10, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York City. NeuroSense will deliver a corporate presentation highlighting the Company's recent clini

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's differentiation, shorten the time to potential commercialization, and significantly reduce overall development costs, complemented by a parallel regulatory pathway in Canada.CAMBRIDGE, Mass., Aug. 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced a redesigned development plan for PrimeC in amyotrophic lateral sclerosis,

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, Alon Ben-Noon, to investors.   Dear Fellow Shareholders,I wanted to take this opportunity to update you on NeuroSense's  preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in Canada and other territories, the strategic discussions under way, and our work on Nasdaq compliance.Our main focus is PARAGON, our pivotal Phase 3 study of

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

Final meeting minutes reflect alignment with Health Canada on the planned content and structure of the ALS submissionCAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that it is targeting December 2026 for the filing of a New Drug Submission ("NDS") with Health Canada for PrimeC, its lead therapeutic candidate for amyotrophic lateral sclerosis ("ALS"). The filing target follows the successful finalization of the Pre-NDS process with Health Canada and the associated meeting minutes. The discussion

EFFECT - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

F-3/A - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker programCAMBRIDGE, Mass., July 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to Health Canada (the "Agency") for PrimeC for the treatment of amyotrophic lateral sclerosis (ALS), following a constructive Pre-New Drug Submission ("Pre-N

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forwardCAMBRIDGE, Mass., July 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced its participation in a key opinion leader (KOL) webinar hosted by Roth Capital Partners titled "A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)." The webinar will bring together leading experts to discuss the current treatment landscape for ALS, persistent unmet medical needs, and emerging th

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALSTDP-43 pathology is present in more than 97% of ALS cases and is widely recognized as a central driver of disease progressionPrimeC demonstrates target engagement with consistent effects across clinical outcomes, survival, and biomarkers, supporting its potential as a disease-modifying therapyCAMBRIDGE, Mass., June 29, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that its Phase 2b

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)